Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era

Clinical Cancer Research

Volumn 18, Issue 16, 2012, Pages 4458-4464

  Cassier, Philippe A ^a   Fumagalli, Elena ^j   Rutkowski, Piotr ^k   Schöffski, Patrick ^l   Van Glabbeke, Martine ⁿ   Debiec Rychter, Maria ^m   Emile, Jean François ^b   Duffaud, Florence ^c   Martin Broto, Javier ^o   Landi, Bruno ^e   Adenis, Antoine ^f   Bertucci, François ^d   Bompas, Emmanuelle ^g   Bouché, Olivier ^h   Leyvraz, Serge ^p   Judson, Ian ^q   Verweij, Jaap ^r   Casali, Paolo ^j   Blay, Jean Yves ^a,i   Hohenberger, Peter ^s  

^a CENTRE LÉON BÉRARD   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c TIMONE HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h University Hospital   (France)

ⁱ UNIVERSITÉ DE LYON   (France)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l Katholieke Universiteit   (Belgium)

^m UNIVERSITY OF LEUVEN   (Belgium)

ⁿ EORTC DATA CENTER   (Belgium)

^o HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^p LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^q ROYAL MARSDEN HOSPITAL   (United Kingdom)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IMATINIB; MIDOSTAURIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CODON; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PDGFRA GENE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865100068     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3025     Document Type: Article

References (25)

1. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Isaac S, Claret-Tournier C, et al. [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhone-Alpes region]. Bull Cancer 2010;7:629-41.
2. Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012;23:353-60.
3. Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 2010;133:141-8.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
5. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23: 5357-64.
6. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 2009;62:613-6.
7. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von MM, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
8. Debiec-Rychter M, Sciot R, Le CA, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
9. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7.
10. Corless CL, Ballman KV, Antonescu C, Blanke CD, Blackstein ME, Demetri GD, et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. ASCO Meeting Abstracts 2010;28:10006.
11. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patientswith advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
12. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247-53.
13. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9.
14. Emile JF, Brahimi S, Coindre JM, Bringuier PP, Monges G, Samb P, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011 Sep 28. [Epub ahead of print].
15. Cassier PA, Ducimetiere F, Lurkin A, Ranchere-Vince D, Scoazec JY, Bringuier PP, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer 2010;103:165-70.
16. Verweij J, Casali PG, Zalcberg J, Lecesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.
17. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di PE, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 Suppl 5:S83-7.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
19. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM, et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004;23: 7780-90.
20. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14:5749-58.
21. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006;131:1734-42.
22. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Reichardt A, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). ASCO Meeting Abstracts 2011;29:LBA1.
23. Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley JGIST Meta-analysis Group. (Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts). ASCO Meeting Abstracts 2007;25:10004.
24. Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, et al. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. Int J Cancer 2011;128: 983-90.
25. Heinrich MC, Griffith D, McKinley A, Presnell A, Ramachandran A. The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. ASCO Meeting Abstracts 2011;29:10012.